Mechanism-based treatments for Alzheimer's disease by Davies, Peter & Koppel, Jeremy
new era in therapy for Alzheimer’s disease
(AD) has begun, with several clinical trials putatively tar-
geting the mechanisms fundamental to the disease
process. At this point, however, there is still controversy
as to which of the targeted processes truly are critical to
disease progression, and how best to inhibit these. In this
brief review, we will attempt to explain the molecular
basis for the different therapies being tested, and to sug-
gest where further knowledge is needed. 
There are three different areas in which mechanism-
based therapies have been developed: i) therapies target-
ing amyloid formation and/or deposition; ii) therapies
targeting tau and/or neurofibrillary tangle formation; and
iii) therapies targeting “neuroinflammation,” or the glio-
sis accompanying formation of amyloid and tangle for-
mation.
We will not consider therapeutic efforts that lack a clear
molecular basis. While the discovery of an effective treat-
ment does not always require information about the
mechanism of the disease, rational translational research
is greatly stimulated when molecular targets are preiden-
tified. 
Therapies targeting amyloid formation
The “amyloid cascade hypothesis”
1 has dominated trans-
lational research on Alzheimer’s disease for over 20 years.
As originally stated, this hypothesis placed emphasis on
the deposition of β-amyloid as the initiating event in the
neuronal dysfunction and death that occurs in brain.
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Treatment for Alzheimer’s disease is entering a new and
exciting phase, with several new drugs beginning clini-
cal trials. Many of these new therapies are based on our
best current understanding of the pathogenesis of
Alzheimer’s disease, and are designed to try to either
slow or halt the progression of the disease. There are
several different theories underlying the current efforts,
and these are briefly reviewed. Therapies directed
against some aspect of -amyloid formation, against
neurofibrillary tangle formation and against the inflam-
matory response are all considered, as are the problems
associated with each area. It is as yet unclear which, if
any, of these approaches will be successful, but the high
level of activity in each of these three fields provides
some hope that an effective treatment for Alzheimer’s
disease is on the horizon.       
© 2009, LLS SAS Dialogues Clin Neurosci. 2009;11:159-169.Implicit in the arguments for this hypothesis is that excess
production of β-amyloid occurs at some point in the dis-
ease process, although this has only rarely been demon-
strated. The major arguments in favor of the hypothesis
are genetic. Mutations in the gene encoding the precursor
of β-amyloid (the amyloid precursor protein, or APP) are
a very rare cause of familial Alzheimer’s disease.
2 The
most common causes of familial Alzheimer’s disease are
mutations in the presenilin 1 gene,
3 and presenilin 1 (as
part of a multisubunit proteolytic enzyme called γ secre-
tase) clearly plays an important role in cleavage of APP
to produce β-amyloid.
4 Less common are mutations in the
presenilin 2 gene,
5 and again this appears to function as
part of a γ secretase complex. Thus all three genes in
which mutation causes familial Alzheimer’s disease are
involved with proteolytic processing of the amyloid pre-
cursor protein.
6
The discovery of amyloid deposits in both diffuse and
neuritic plaques as a major characteristic of Alzheimer’s
disease pathology has been interpreted to mean that
there is increased amyloid production. However, deposi-
tion could clearly be the result of decreased clearance,
degradation, or of some other process occurring in the
tissue. Recent data from three different groups has sug-
gested that most of the familial Alzheimer’s disease
mutations in APP and presenilins 1 and 2 actually result
in reductions in the rate of cleavage of the APP, and
reduced rates of β-amyloid production.
7-9This is clearly
difficult to reconcile with the huge increase in amyloid
deposits in brain tissue, and has led to modifications in
the original pathogenic cascade model. 
Indeed, over the last 10 years, more and more groups
have moved away from the original formulation of the
amyloid cascade hypothesis, in large measure because it
is clear that there is only very limited neurotoxicity asso-
ciated with deposition of β-amyloid. This is especially
true in mice. A large number of transgenic mice have
been made in which overexpression of mutant human
APP (sometimes combined with a mutant presenilin1
gene) drives deposition of large amounts of β-amyloid in
the brain. The vast majority of these transgenic mice do
not have evidence of neuronal degeneration or cell
death, nor do they feature neurofibrillary tangle forma-
tion. This result is not what would be expected if the orig-
inal proposal of the amyloid cascade hypothesis were
correct. These and other results have led to modifications
of the original hypothesis that propose that it is not depo-
sition of β-amyloid that is the initiating event in pathol-
ogy, but the formation of a soluble “toxic species” of β-
amyloid peptides.
10,11Along this line of reasoning, some
have suggested that the deposition of β-amyloid may in
fact be neuroprotective,
12,13 with resultant sequestration
of potentially toxic species. These toxic species are pro-
posed to be oligomers, small aggregates of 2 to 12 pep-
tide molecules, usually of the 42 amino acid long β-amy-
loid peptide.
11,14There remains considerable controversy
about the precise molecular nature of the toxic species,
and about the mechanism by which this species produces
detrimental effects on neurons. The most common expla-
nation is that synaptic disruption is the immediate toxic
event,
15 although precisely how this happens in the
Alzheimer’s disease brain remains poorly understood.
Whether amyloid deposits or some soluble species is con-
sidered to be the initiating factor in the disease, these
approaches are considered as “toxic gain of function
models,” in which disease is proposed to be caused by the
formation of novel molecular entities that cause toxicity.
There is now a fairly vocal minority of researchers who
have proposed that it is not actually the formation of any
β-amyloid species that is the problem. All of the known
familial Alzheimer’s disease mutations disrupt prote-
olytic processing of the amyloid precursor protein, and
probably several other proteins normally cleaved by the
γ secretase complex. If the production of a toxic β-amy-
loid species could be considered as a “toxic gain of func-
tion” in the majority view, the minority view would
regard familial Alzheimer’s disease mutations as “loss of
γ secretase function.” While this view would appear con-
sistent with the apparent reductions in the rate of cleav-
age of the APP (and some other substrates) noted with
mutant APP or presenilin 1, a major problem is to pro-
vide an explanation for the abundant deposition of β-
amyloid in the Alzheimer brain. If less amyloid is made,
why is there so much deposition? 
Regardless of the position taken on the molecular details
of APP processing in Alzheimer’s disease, it remains true
that the vast majority of attempts at therapy for
Alzheimer’s disease to date are directed at reducing the
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Translational researchamount of β-amyloid in brain. These attempts fall into
four different groups, depending on the approach.
Use of inhibitors of amyloid aggregation
The first interventional amyloid approach, based on the
unmodified amyloid cascade hypothesis, was an attempt
to prevent amyloid aggregation and/or to disrupt pre-
formed amyloid aggregates. Enthusiasm for this mecha-
nism of intervention has waned somewhat, in tandem
with the original version of the amyloid cascade hypoth-
esis. Although a major clinical trial of an aggregation
inhibitor, called Alzhemed
16,17 was carried out recently,
results appear to have been negative, although some
debate about variability between clinical trial sites has
prevented a clear statement on this issue. Given the pos-
sibility that deposition of β-amyloid in tissues sequesters
toxic species, and that disruption of deposition may
increase toxic effects, further attempts along these lines
appear unlikely. 
Use of inhibitors of β-secretase
The proteolytic enzyme that cuts APP to liberate the N-
terminus of the β-amyloid peptide, β secretase or
BACE1, was identified and cloned by several groups, and
it appears to be a single protein that cleaves APP and
only a few other protein substrates.
18,19 Mice in which the
BACE1 gene is knocked out appear relatively normal,
surviving into adulthood with subtle, if any, neuronal
defects.
20 BACE1 appears to be essential for generation
of β-amyloid, such that mice overexpressing mutant
human APP do not generate any measurable β-amyloid
in the absence of the mouse BACE1 gene.
21 Clearly, the
generation of specific inhibitors of BACE1 is an obvious
and attractive prospect for prevention of production of
β-amyloid. X-ray crystallography has been used to deter-
mine the precise structure of BACE1, and this should
facilitate the development of inhibitors.
22The nature of
the active site of this enzyme presents significant chal-
lenges to the development of small molecule inhibitors
that can cross the blood-brain barrier,
23,24 but it is very
likely that such compounds will be forthcoming. Given
the absence of a major detrimental effect of the knock-
out of the BACE1 gene, inhibition of BACE1 appears
unlikely to result in severe side effects (but see ref 25). 
It is important to emphasize that success with BACE1
inhibitors will be dependent, to a large extent, on the
validity of the “toxic gain of function” model, as sup-
pression of BACE1 activity seems certain to reduce
rates of production of β-amyloid by reducing rates of
cleavage of APP. The challenge here is that if most
mutations in APP and presenilin 1 also result in reduced
rates of cleavage, and produce disease by this mecha-
nism, one would expect an acceleration of disease pro-
gression on inhibition of either BACE1 (or γ secre-
tase—see below). One of the most significant problems
here is the absence of appropriate animal models. As
mentioned above, mice with extensive amyloid depo-
sition driven by overexpression of a mutant human APP
gene do not develop a significant neurodegeneration.
Thus while studies with BACE1 inhibitors could read-
ily be performed in these mice to show reductions in
amyloid deposition, few of the other features of
Alzheimer’s disease are evident in these mice, so that
the effects of these compounds on the pathology and/or
clinical features of Alzheimer’s disease will remain
untested until human trials are conducted. 
Use of inhibitors of γ secretase
The problems with the use of γ secretase inhibitors are
somewhat similar to those of inhibiting BACE1, although
there are some notable distinctions. Knockout of vital
components of γ secretase (presenilin 1, for example)
does not produce viable mice unless the knockout is con-
ditional
26 (effectively unless the knockout is engineered
to occur only in adult mice). The problem here is that γ
secretase cleaves numerous proteins as well as APP, and
at least some of these proteins (eg, Notch1
27) play critical
roles in brain development. Their role in the adult animal
is less clear, although knockout of both presenilins 1 and
2 in adult animals results in a striking neurodegenera-
tion.
28,29 However, complete inhibition of γ secretase is not
what is intended by therapeutics, and the question still
remains about whether the production of β-amyloid can
be reduced without unacceptable consequences, these
resulting presumably from reductions in the rate of pro-
cessing of other γ secretase substrates. Preliminary
reports appear to suggest that this is possible,
30,31 and it
appears that a large-scale phase 3 clinical trial of a γ sec-
retase inhibitor is now underway. Again, success would
seem to be dependent largely on the validity of the “toxic
gain of function” model. There is perhaps the more direct
concern here that again, the treatment exacerbates rather
than interrupts the disease as reductions and not
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161increases in the activity of γ secretase appear to result
from mutations, particularly in presenilin 1.
Finally, much has been made of the effects of mutations
in presenilin 1 (and perhaps presenilin 2) on the ratio of
β-amyloid 40 to β-amyloid 42 produced by APP cleav-
age.
7These two peptides both appear to be produced by
normal γ-secretase function, and it is true that many of
the mutations shift the pattern of cleavage of APP so that
despite the overall reduction in APP cleavage, relatively
more of the 42 amino acid peptide is produced, decreas-
ing the 40/42 ratio.
4The β-amyloid 42 peptide does aggre-
gate more readily than β-amyloid 40, and is more neuro-
toxic in in vitro assays.
32,33 The “toxic gain of function”
model suggests that this is critical to the cascade of events
that ensue. Precisely what inhibitors of γ secretase do to
this ratio is unclear, although at least some published
data indicates that suppression of γ secretase activity can
occur without a significant change in the 40/42 ratio.
7
Perhaps this will prove critical to the success—or fail-
ure—of secretase inhibition in general. Only the clinical
trials seem likely to provide this answer. 
Use of antibodies, presumably to remove amyloid from
the brain
Antibody approaches to reducing β amyloid in brain
began with the spectacular studies of Schenk and col-
leagues, who immunized mutant human APP transgenic
mice with β-amyloid peptides, and reported very signifi-
cant reductions in amyloid deposition in these mice.
34
Several others have confirmed and extended this early
work,
35,36 and human trials of “amyloid vaccination” have
already been carried out. This is not the forum for dis-
cussing the controversial nature of these studies: suffice
it to say that the results were far from the ideal. A num-
ber of patients developed an encephalitis,
37 and in some
cases this appeared to be disastrous. Whether or not
there was any benefit remains highly dubious,
38,39 but
from a mechanistic viewpoint this approach raises a fun-
damental question: just how is an immune response to
amyloid peptides supposed to reduce β amyloid concen-
trations in the brain? 
Active immunization of transgenic mice with human
amyloid peptides can produce the full range of B- and T-
cell responses, in part because the human and mouse
peptides differ in sequence—the human peptide is “for-
eign” to mice. Presumably the T-cell responses are what
led to the encephalitis in humans immunized with human
peptides, consistent with the induction of an autoimmune
response.
36,40,41 But why would a B cell—an antibody-pro-
ducing response—be helpful? 
Generally, antibodies in the circulation penetrate into the
brain in only low concentrations.
42 However, studies again
in transgenic mice suggested that passive immunization,
in which antibodies to β-amyloid were injected into the
mice, have also been reported to cause significant reduc-
tions in the deposition of β-amyloid in the brains of the
mice.
43,44 There are two basic ideas of how this might
work. First, it seems possible that while only a very small
fraction of the injected antibodies makes it across the
blood-brain barrier, this is sufficient to bind enough β-
amyloid to reduce deposition.
45,46Antibody binding to β-
amyloid in the brain may also activate the microglial (and
possibly astrocytic) mechanisms that can reduce amyloid
deposition.
44,47 Critical in this formulation is the penetra-
tion of antibody into the brain.
A second proposed mechanism is what has been called
the “peripheral sink hypothesis.” In this case, antibody
binding to β-amyloid in the blood is thought to result in
a sharp concentration gradient between the blood and
the brain, such that β-amyloid movement from brain to
blood is accelerated, and β-amyloid concentrations drop
sharply and thus reduce the rate of deposition.
48
Although this mechanism initially seems highly unlikely,
there is evidence for transport of β-amyloid from brain
to blood, at least under some circumstances.
49 Perhaps
it is unnecessary for the antibody to reach the brain at
all. 
The first clinical trials of “passive immunization” as a
treatment for Alzheimer’s disease appear to be under-
way, and preliminary results were reported in mid-2008.
In passive immunization of transgenic mice, at least some
antibodies appear to cause a shift in the localization of β-
amyloid from deposits in the tissue to deposition in ves-
sel walls, with some microhemorrhages reported.
43
Human trials reported some vasculitis as a side effect in
groups receiving the highest doses of antibody, although
effects on rates of cognitive decline did not appear to be
large, if measurable at all. Further trials of passive immu-
nization are underway, in some cases using intravenous
immunoglobulin G (IgG) fractions, with the presumption
that natural IgG fractions—prepared by isolation of IgG
from many thousands of donors—contain sufficient con-
centrations of anti-β-amyloid antibodies to reduce amy-
loid deposition.
50,51 Whether this will prove a viable
approach to therapy is as yet unclear. 
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Tau, a microtubule-associated protein, is the major pro-
tein of neurofibrillary tangles. The amyloid cascade
hypothesis considers that changes in tau leading to neu-
rofibrillary tangle formation to be secondary events, and
this viewpoint resulted in a neglect of this area in terms
of therapeutics (with a few notable exceptions). A change
in perception resulted from the discovery of mutations in
the human tau gene that caused the neurodegenerative
diseases collectively called frontotemporal dementia or
tauopathies.
52These diseases are characterized by mas-
sive degeneration of frontal and temporal cortex, fre-
quently with Parkinsonian features and sometimes fea-
turing extensive tangle pathology.
53 Since the initial
reports, it has become clear that a number of single
amino acid changes in tau result in neuronal degenera-
tion, and that even mutations that do not alter the amino
acid sequence can cause disease, by altering the splicing
of the tau mRNA.
54 It appears that even quite small
changes in tau can cause neuronal death (at least in the
frontal and temporal cortex), and this notion has led to
the hypothesis that the changes in tau seen in
Alzheimer’s disease may be responsible for cell death
even if they are secondary to β-amyloid toxicity.
55,56This
hypothesis has received some support from experimen-
tal work in which β-amyloid has been shown to have less
toxicity in cells or mice lacking tau.
57-59 Prevention of tau
pathology has begun to emerge as a viable approach to
prevention of neurodegeneration, although efforts in this
area lag significantly behind the anti-amyloid research.
There are currently two major approaches in this area: i)
prevention of tau aggregation; and ii) inhibition of tau
phosphorylation. 
Prevention of tau aggregation
The major function of tau in neurons is thought to be the
stabilization of microtubles, and tau can be demonstrated
to both increase the rate of assembly of tubulin into
microtubules and stabilize existing microtubules.
60This
activity appears to be controlled by phosphorylation of
tau, in that phosphorylation of tau renders it less efficient
in promoting assembly, and is believed to dissociate tau
from assembled microtubules. Tau is ordinarily a soluble
protein, but forms insoluble, filamentous aggregates in
the course of neurofibrillary tangle formation. Early
methods for purification of tangles took advantage of this
insolubility, and employed harsh detergent and acid
extraction techniques to dissolve away contaminating
proteins.
61,62 Both toxic gain of function and loss of func-
tion models have been proposed for tau’s role in neu-
ronal degeneration. The formation of tau aggregates may
be toxic to neurons,
63 or conversely, conversion of tau into
insoluble polymers may reduce the effectiveness of tau
in stabilizing microtubules. It is still too early in this
research to decide which model is more plausible.
The mechanisms responsible for the conversion of a nor-
mally soluble monomeric protein into the insoluble fil-
amentous aggregates have been the subject of intense
study and the target for some drug development.
Although tau in neurofibrillary tangles is hyperphospho-
rylated (see below),
64 there is still much debate about the
role of phosphorylation in aggregation of tau. Indeed,
many of the studies of tau aggregation have shown the
formation of filamentous aggregates from nonphospho-
rylated tau,
65,66 and have used such systems to screen for
potential inhibitors of tau aggregation. These studies usu-
ally include polyanions such as heparin, RNA,
65 or arachi-
donic acid
67 to stimulate tau aggregation. Using such a
system, unpublished results apparently revealed that
methylene blue could inhibit tau aggregation, and this
compound, under the name Rember, has been reported
to be effective in preventing decline in clinical test scores
in patients with Alzheimer’s disease. Abstracts claiming
to describe the effects of Rember on tau aggregation in
cell culture models, in tau transgenic mice, and even in
human imaging studies have also appeared, although
peer-reviewed data is not yet available to support these
claims. Rember appears to be the first tau aggregation
inhibitor to reach phase II clinical trials but whether or
not the results reported can be replicated remains to be
seen. 
Prevention of tau phosphorylation
Tau in the adult human or animal brain is a phosphopro-
tein, with an average of about 2 moles of phosphate per
mole of protein, while tau isolated from the Alzheimer
brain (usually as neurofibrillary tangles) contains 6 to 8
moles of phosphate per mole of protein,
68 and there is thus
little debate about the fact that tau is hyperphosphory-
lated.
69The majority of the translational research on tau
has centered on the development of drugs to inhibit this
hyperphosphorylation, with the implicit assumption that
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sible for this increase in tau phosphorylation. Formally, it
is possible that a deficiency in a protein phosphatase is as
likely a culprit as an abnormal kinase activity, but it is usu-
ally easier to develop enzyme inhibitors than to develop
enzyme activators. Careful analysis of the sites on tau at
which phosphorylation is increased has suggested that
these are the result of activation of more than one protein
kinase.
70This conclusion derives from work which identi-
fied hyperphosphorylation sites with a proline residue fol-
lowing a serine or threonine, this being required for the
activity of the “proline-directed kinases,”
71 as well as phos-
phorylation at sites that lack a proline (where phosphory-
lation is presumably performed by other kinases). It
appears probable that there is a cascade of kinase activi-
ties,
72 and the great difficulty has been in trying to identify
a single critical kinase responsible for conversion of tau
into neurofibrillary tangles.
Several protein kinases have been discussed as potential
targets for therapeutics. Glycogen synthase kinase
(GSK)3β, cyclin-dependent kinase (CDK)5 and extracel-
lular signal-related kinase (ERK)2 seem to be the most
commonly selected targets, and there has been at least
some evidence published to suggest that all three kinases
can be found associated with tangles in the brains of
patients with Alzheimer’s disease.
73 For GSK3β, it is well
established that this kinase can phosphorylate tau in cells
in culture
74 and in the brains of transgenic mice,
75 espe-
cially when a constitutively active kinase is used. There is
also some evidence that GSK3β activity can accelerate
the aggregation of tau when introduced into some tau
transgenic mice,
76 although in certain mice the introduc-
tion of GSK3β actually resulted in less aggregation.
75,77
A large number of inhibitors of GSK3β have been devel-
oped over the last few years, and two well-known agents,
lithium and sodium valproate, are also thought to act at
least in part through inhibition of this kinase.
78The use of
lithium with its attendant side effects and potential for tox-
icity poses a challenge to long-term use in demented
elderly patients, and no substantial study of possible effi-
cacy in Alzheimer’s disease has yet been published (but
see refs 79-82). Nonetheless, lithium, as well as some of
newer synthetic GSK3 inhibitors, have been used in sev-
eral tau transgenic drosophila
83,84 and mouse models, and
there are reports of reductions in tau phosphorylation and
aggregation.
85,86Whether the newer inhibitors will make it
into clinical trials is uncertain. GSK3 is involved in numer-
ous cellular processes, including glycogen storage, control
of cell division, and perhaps neuronal polarity. There is an
obvious concern about the potential for side effects from
inhibition of this kinase. Sodium valproate is apparently
being tested in a large clinical trial in Alzheimer’s disease
patients
87 although no data are yet published. 
Among the remaining candidate protein kinases, there is
great interest in CDK5, the activity of which appears to
play a very important role in brain development.
88
Transgenic mice in which CDK5 activity is activated (by
overexpression of the p25 activator) in adult brain show
evidence of a striking neurodegeneration with some tau
pathology.
89,90 It has been reported that the concentration
of p25 is elevated in the human AD brain,
91 although the
validity of the original report has been questioned.
92
Inhibitors of CDK5 appear to have some influence on the
development of pathology in some tau transgenic mice,
although the effects reported are not large.
93There are as
yet no reports of the use of CDK5 inhibitors in humans. 
Finally, activated ERK2 has been reported to be associ-
ated with neurofibrillary tangles in human Alzheimer’s
disease.
94A rather nonspecific inhibitor of this kinase was
used in tau transgenic mice, with apparently some ben-
eficial results,
95 but as with GSK3 and CDK5, there are
concerns that the multifaceted role of this kinase in cel-
lular metabolism would appear to lower the probability
that such inhibitors will make it into human studies. 
One of the largest barriers to work of this type has been
the lack of good research tools. Compounds that can
specifically inhibit the activity of a single kinase (eg,
GSK3β) and can efficiently cross the blood-brain barrier
would allow better definition of the kinases that phos-
phorylate tau in vivo. There are few such compounds
available to the research community. Precise definition
of the kinases responsible for tau phosphorylation in the
normal adult brain would be very helpful. As indicated
above, there are a large number of different transgenic
animal (and fly) models in which tau appears to be
hyperphosphorylated, but it has been very difficult to dis-
sect the signal transduction pathways responsible for this
phosphorylation in any given model. There is, as always,
also the concern about the fidelity of the models: how
accurately do they reflect the process of tau hyperphos-
phorylation that occurs in human Alzheimer’s disease? 
Antibody approaches to tau pathology?
There is a single report in which a “vaccination” approach
to the treatment of tau pathology was carried out in a tau
164
Translational researchtransgenic mouse model, with some apparent benefit.
96 It
is hard to work out how this might work, as in contrast to
the amyloid pathology, tau aggregates inside neurons. Are
antibodies able to access abnormal tau within neurons?
This seems very unlikely, but further studies along these
lines appear to be going on in several transgenic mouse
models. If this approach does produce promising results, it
may prove difficult to unravel the mechanism by which
this happens.
Therapies targeting “neuroinflammation”
The idea that the gliosis (microgliosis and astrocytosis,
together called neuroinflammation) that accompanies
the amyloid and tau pathology of Alzheimer’s disease
plays an active role in the neurodegenerative process has
been much discussed over the last 15 years. Activated
microglia, and perhaps activated astrocytes, can produce
a variety of cytokines and other factors (especially reac-
tive oxygen species, ROS) that in some circumstances
appear to be neurotoxic. There is also evidence from epi-
demiological studies that chronic use of nonsteroidal
anti-inflammatory drugs (NSAIDs) was associated with
a significant reduction in the risk for development of
Alzheimer’s disease.
97-99 Given the very widespread use
of a number of different NSAIDs and other anti-inflam-
matory agents, a series of clinical trials were performed
over the last decade. Despite some initial apparently pos-
itive effects in nonblinded studies, formal trials using
prednisone,
100 rofecoxib,
101-103 naproxen,
104 celecoxib,
105 tri-
flusa
106 and hydroxychloroquin
107 all yielded negative
results. More recently, (R) flubiprophen, a derivitive of
an NSAID that was also reported to have activity as a γ
secretase inhibitor,
108,109 was reported to be without effect
in a large clinical trial with several hundred patients with
Alzheimer’s disease. It is often easy to criticize a partic-
ular clinical trial for using only a limited number of doses
of a few different compounds in a relatively small sam-
ple of patients. However, the results reported to date
from studies testing potential anti-inflammatory drugs in
patients with Alzheimer’s disease are unanimous in their
inconsistency with the idea that targeting this mechanism
is likely to be fruitful. It remains possible that a better
understanding of the relationship between the microglio-
sis/astrocytosis of Alzheimer’s disease and classically
defined peripheral inflammation would be worthwhile.
As has been pointed out by others, the neuroinflamma-
tion of Alzheimer’s disease is not classical inflammation,
and the role of this response and the reaction to anti-
inflammatory agents might be quite different.
110 Despite
these caveats, it seems unlikely that additional clinical tri-
als of agents of this type will be carried out in the new
future.
Conclusions
We have briefly reviewed the approach of work aimed at
developing mechanism-based therapies for Alzheimer’s
disease. Almost all of the individual areas could be the
subject of a book, rather than a chapter or a section in a
chapter. We have also only attempted to cover the major
areas of research, and have left out several potentially
very exciting areas that are at earlier stages of develop-
ment. One such example is the “mitotic hypothesis,”
which suggests that much of the pathology in Alzheimer’s
disease results from inappropriate activation of cell cycle
machinery in terminally differentiated neurons.
111-113 A
recently published transgenic mouse study shows strik-
ing, Alzheimer-like degeneration from forced activation
of the cell cycle with a viral oncogene.
114The huge num-
ber of labs attempting to develop new agents for cancer
treatment (antimitotics) may be expected to yield drugs
that might be tested in such animal models, and perhaps
in patients with Alzheimer’s disease. We have also not
discussed the very exciting area around apolipoprotein
E (ApoE). There is now no doubt that a major risk fac-
tor for the development of Alzheimer’s disease
115-119 (and
perhaps other neurological diseases
120-122) is the possession
of one or more ApoE4 allele. Despite the wealth of evi-
dence implicating ApoE4, there is as yet very little indi-
cation of a target for therapy in this area. It is to be
hoped that all the basic research activity will change this
situation soon. 
We do not yet have truly effective therapy for
Alzheimer’s disease, but as the above review should
make clear, there are several potential paths to such a
treatment. It is our hope that all the activity in this area
will soon yield real benefits to those who suffer from this
dreadful disease.  ❏
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